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It is assumed that tumor size may be associated with malignant tumor conversion. However, the mol-
ecules responsible for determination of tumor size are not well understood. We counted the number of
intestinal tumors in 8, 12 and 30-week-old ApcMin/þ mice and measured tumor sizes, respectively. Genes
involved in determining tumor size were examined using microarray analysis. Cultured cells were then,
transfected with a mammalian expression vector containing a candidate gene to examine the functional
role of the gene. The effect of forced expression of candidate gene on cell growth was evaluated by
measuring the doubling time of the cultured cells and the growth of grafted cells in nude mice. Unex-
pectedly, microarray analysis identiﬁed trefoil factor family 2 (Tff2) rather than growth related genes
and/or oncogenes as a most variable gene. Overexpressing Tff2 in cultured cells reduced doubling time
in vitro and rapidly increased xenograft tumor size in vivo. We found Tff2 as a novel important factor that
to be able to enlarge an intestinal tumor size.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
It is well known that risk of malignant conversion increases
along with tumor size; furthermore, tumor size is correlated with a
risk of metastasis [1] and is also a key factor in determining effec-
tive therapeutic strategies for cancer. For instance, when a colo-
rectal tumor increases in size over 100 mm, the risk of permeation
andmetastasis also increases [2]. As far as we know, at present little
is known about the genes determining tumor size and its rela-
tionship to the tumor enlargement.
In our previous study, we generatedMdr1ae/eApcMin/þ genotype
mice by crossing Mdr1a (multi-drug resistance; Mdr) gene




Inc. This is an open access article uintestinal tumorigenesis directly [3,4], and that the number of in-
testinal tumors was decreased when the function of Mdr1a was
inhibited by verapamil [5]. Inhibition of Mdr1a could decrease the
number of tumors, but it could not decrease the tumor size. Thus, in
this study, we aimed to identify the genes that deﬁne tumor size in
an adenoma, the premalignant lesion of intestinal cancer.
To this end, we used ApcMin/þ mice, which spontaneously
develop multiple intestinal polyps caused by a mutation in the Apc
gene. Thesemice have been extensively used in research on familial
adenomatous polyposis (FAP); this mutation is also observed in
>80% of sporadic colorectal cancers [6]. To explore factors deter-
mining tumor size, we analyzed size-dependent gene expression
proﬁles in ApcMin/þ mice.
2. Materials and methods
2.1. Mice
ApcMin/þ (C57BL/6J) mice were obtained from Jackson Labora-
tories (Bar Harbor, Maine, USA), and nude mice (BALB/cA nu/nu)nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
K. Fujimoto et al. / Biochemical and Biophysical Research Communications 463 (2015) 859e863860were purchased from CLEA Japan (Tokyo, Japan). All mice were
maintained under speciﬁc pathogen-free conditions. We used 29
ApcMin/þ and 17 nudemice. All animal experiments were performed
according to the Guidelines for Animal Experiments in the Faculty
of Pharmaceutical Sciences, Nagasaki International University
(Nagasaki, Japan).
2.2. Count the number of intestinal tumors and statistical analysis
Intestinal tumor counts and statistical analyses were performed
as previously described [4,7]. The number of cells in in vitro ex-
periments was counted by TC10 Cell counter (Bio-Rad, CA, USA).
Doubling time was calculated using doubling time program (http://
www.doubling-time.com/compute.php). All statistical analyses
were performed using GraphPad Prism 5 software (GraphPad
Software Inc., CA, USA). We calculated P value by unpaired t-test
and polynomial regression analysis about in vitro and in vivo ex-
periments, respectively.
2.3. Extraction of total RNA and microarray analysis
Intestinal tumor excision and total RNA extraction from tumor
samples were performed according to previously published
methods [7]. We used twomice and excised three intestinal tumors
of each small and large size from each mouse (size category would
be described in Results). Total RNA was reverse transcribed using
the High Capacity RNA-to-cDNA Kit (Applied Biosystems, CA, USA).
Gene expression in the intestinal tumors was analyzed using the
BeadsChip Mouse WGe6 Illumina microarray (Illumina, Inc., CA,
USA) according to the manufacturer's protocol. We independently
examined each microarray of the excised tumor and repeated the
procedure two times.
2.4. Quantitative real-time polymerase chain reaction analysis
Real-time polymerase chain reaction (PCR) was performed us-
ing Fast SYBR Green Master Mix (Applied Biosystems, CA, USA)
according to the manufacturer's protocol. We excised 26 and 17
intestinal tumors, small and large size respectively, from three
mice. Primers used were mouse trefoil factor family 2 (Tff2) (50-
TGCTCTGGTAGAGGGCGAG-30 and 50-CGACGCTAGAGTCAAAGCAG-
30) and 18SrRNA (50-CGGCTACCACATCCAAGGAA-30 and 50-
GCTGGAATTACCGCGGCT-30) as an endogenous control. Melting
curve for each PCR amplicon was analyzed to assess primer set
speciﬁcity.
2.5. Recombinant plasmid construction
To construct a plasmid vector for mammalian expression, Tff2
cDNA was ampliﬁed using the high-ﬁdelity DNA polymerase KOD
FX (TOYOBO, Osaka, Japan) with primers (50-AAGTAAGAGCTCCA-
GACATGCGACCTCGAGGT-30 and 50-AAGTAAGGATCCGTAGTGA-
CAATCTTCCACAG-30). SacI and BamHI recognition sites were added
to the 50 ends of these primers. The resultant PCR fragment was
digested with SacI and BamHI and was cloned into a similarly
digested vector pEGFP-N3 to yield the expression vector pEGFP-N3-
Tff2.
2.6. Cell culture and transfection
The human colon cancer cell line DLD-1 (ATCC, Manassas, USA)
was cultured in Roswell Park Memorial Institute 1640Medium (Life
Technologies Gibco®, Grand Island, USA) supplemented with 10%
fetal bovine serum (FBS; Gibco®), 2 mM glutamine, 1% pen-
icillinestreptomycin mixed solution (ﬁnal, 100 U/mL and 100 mg/mL, respectively; Nacalaitesque, Kyoto, Japan) at 37 C in a 5% CO2
humidiﬁed incubator. The MDCKII cell line (kindly provided from
Prof. Yoshikatsu Kanai at Osaka University) was cultured in Eagle's
minimum essential medium (Gibco®) with 5% FBS, 1% pen-
icillinestreptomycinmixed solution at 37 C in a 5% CO2 humidiﬁed
incubator. DLD-1 and MDCKII cells were transfected with the
expression plasmid pEGFP-N3-Tff2 using Lipofectamine 2000 (Life
Technologies Invitrogen®, CA, USA), based on the manufacturer's
recommendation. Mock transfections were performed as a control.
Each transfection experiment was repeated three times.
Stable clones harboring pEGFP-N3-Tff2 and the corresponding
mock controls were constructed for the mouse xenograft experi-
ments. Stable transfectants were selected by adding 600 mg/mL
G418 to transfected DLD-1 cells. The G418-resistant clones were
obtained approximately 2 weeks after initiation of selection. The
clones were picked using cloning rings and were expanded for 4
weeks. Several G418-resistant cell lines each were selected
from the mock-transfected and pEGFP-N3-Tff2-transfected cells,
respectively.
2.7. Mouse xenograft experiment
We prepared eight and nine nude (BALB/cA nu/nu) mice for
transplantation of DLD-1 cells that stably expressed Tff2 and mock
plasmid, respectively. The nude mice were subcutaneously inocu-
lated in the right ﬂank area with 107 cells. Each group was divided
in two; half were injected with one of the two stable clones and the
other half were injected with another clone. Each tumor volume
was calculated as (length/2)  (width2). After the tumor volume
had reached to approximately 200 mm3, we measured the xeno-
graft every 3 or 4 days. Then we calculated the respective means
and standard deviation value for each of Tff2 and mock stable
clones. The xenograft model experiment was repeated twice.
3. Results
3.1. Intestinal tumor size of 2.5e3 mm was most prevalent in 30-
week-old ApcMin/þ mice
To reveal the mechanisms underlying tumor size determination,
we examined tumors in the small intestines of 8, 12 and 30-week-
old ApcMin/þmice (N ¼ 6, 11 and 12, respectively). The line graph of
Fig. 1 showed the frequency of each tumor size in the different
weeks old ApcMin/þmice.We found that the frequency of tumor size
demonstrated a single peak in each ages. The 30-week-old ApcMin/þ
mice had the most variable size of intestinal tumors. To identify the
genes involved in determining intestinal tumor size, we analyzed
tumors with different size using microarrays. We compared tumors
larger than peak size in diameter (4e5 mm in diameter; designated
as L) with that smaller than peak size (2 mm in diameter, desig-
nated as S) in 30-week-old ApcMin/þ mice. The extracted tumors
were simultaneously subjected to pathological examination, and
we conﬁrmed that almost all extracted tumors were adenomas.
However, 60% of the large size tumors extracted revealed adeno-
carcinoma (see Additional ﬁle 1).
3.2. The largest variation in gene expression level among large and
small intestinal tumors was detected for Tff2
Microarray analysis revealed that expression levels of some
genes greatly increased with tumor size; most notable was Tffs
(Table 1). We examined the expression level of Tffs and other genes
with increased expression using quantitative real-time PCR (qRT-
PCR). We veriﬁed that the difference of the mean expression level
of Tff2was seven times higher in large tumors than in small tumors
Fig. 1. Frequency of the intestinal tumor size in 8, 12 and 30-week-old ApcMin/þmice. We used 6, 11 and 12 mice and excised a total of 403, 628 and 892 intestinal tumors in 8,12 and
30-week-old ApcMin/þ mice. The number of tumors per every 0.2 mm size (8 and 12-week-old) and 0.5 mm (30-week-old) was totaled, the frequency was calculated by dividing the
total sums by the number of all intestinal tumors in each ages mice and the value was deﬁned as the frequency of the intestinal tumor size.
Table 1
Microarray data analyzing small and large tumors.
ProbeID Gene
Symbol
Deﬁnition Signal Large/Small Accession RefSeq_ID EntrezID
Small Large Zscore Ratio
3780386 Tff2 “Mus musculus trefoil factor 2
(spasmolytic protein 1) (Tff2), mRNA.”
594.3 ± 164.6 6527.3 ± 3229.4 6.3 ± 1.3 10.3 ± 2.6 NM_009363.3 NM_009363.3 21785
460754 Tff1 “Mus musculus similar to pS2m
(LOC100041004), trefoil factor 1(Tff1)
mRNA.”
218.4 ± 34.9 2419.1 ± 1524.6 5.6 ± 0.1 10.2 ± 5.3 XM_001475697.1 XM_001475697.1 100041004
3290402 Pgc “Mus musculus progastricsin
(pepsinogen C) (Pgc), mRNA.”
197.5 ± 58.0 1448.1 ± 725.8 5.1 ± 0.8 6.8 ± 1.7 NM_025973.3 NM_025973.3 109820
1510373 Aqp5 “Mus musculus aquaporin 5
(Aqp5), mRNA.”
295.4 ± 79.4 1677.1 ± 27.3 4.9 ± 0.7 6.1 ± 1.5 NM_009701.4 NM_009701.4 11830
3120497 Nptx2 “Mus musculus neuronal
pentraxin 2 (Nptx2), mRNA.”
262.2 ± 84.4 1181.1 ± 100.4 4.3 ± 0.6 4.9 ± 1.2 NM_016789.2 NM_016789.2 53324
2680113 Ttr “Mus musculus transthyretin
(Ttr), mRNA.”
299.5 ± 110.0 1246.0 ± 189.4 4.1 ± 0.6 4.5 ± 1.0 NM_013697.3 NM_013697.3 22139
6960451 F13a1 “Mus musculus coagulation
factor XIII, A1 subunit (F13a1), mRNA.”
174.1 ± 89.8 626.2 ± 306.4 3.7 ± 0.8 3.7 ± 0.1 NM_028784.2 NM_028784.2 74145
50402 Abpb “Mus musculus androgen binding
protein beta (Abpb), mRNA.”
470.8 ± 14.1 1699.9 ± 87.1 3.7 ± 1.1 3.6 ± 0.1 NM_001100464.1 NM_001100464.1 233099
4590025 Habp2 “Mus musculus hyaluronic acid
binding protein 2 (Habp2), mRNA.”
594.1 ± 47.4 2042.0 ± 324.6 3.6 ± 1.3 3.4 ± 0.3 NM_146101.1 NM_146101.1 226243
4760040 Habp2 “Mus musculus hyaluronic acid
binding protein 2 (Habp2), mRNA.”
1022.7 ± 72.6 3229.3 ± 474.7 3.4 ± 1.3 3.1 ± 0.2 NM_146101.1 NM_146101.1 226243
Mean signal value±standard error of the mean (SEM, n ¼ 6, three intestinal tumours per one mouse).
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expression level in microarray analysis and qRT-PCR. As a conse-
quence, we selected Tff2 for further functional studies.3.3. Tff2 accelerated cell proliferation and increased xenograft
tumors
To assess whether Tff2 was directly involved in tumor growth,
we compared the growth rate of DLD-1 cells with and without Tff2
transfection. DLD-1, a human colon adenocarcinoma cell line, has a
genetic variation in APC [8]. The doubling time of Tff2-transfected
cells tended to be shorter than that of mock cells (22.4 ± 0.5 vs.
26.7 ± 1.6 h, respectively) (Fig. 2A). Furthermore, we performed this
same experiment using MDCKII cells, which are epithelial-like cells
established from the kidney of Canis familiaris. These cells also
displayed a large difference in doubling time between the Tff2-
transfected andmock cells (20.85 ± 0.32 vs. 32.35 ± 0.72 h, P < 0.05,
unpaired t-test), as shown in Fig. 2B.
To examine the possible role of Tff2 in tumor size determination
in vivo, we performed hypodermic injection of Tff2-and mock-transfected DLD-1 cells into eight and nine nude mice, respec-
tively. A plot of tumor volumes against time demonstrated that
Tff2-transfected xenograft tumors grew more rapidly than the
mock-transfected cells obviously (Fig. 2C) (polynomial regression
analysis, P < 0.0001).4. Discussion
As far as we know, this is the ﬁrst report that suggests Tff2 is a
factor responsible for tumor enlargement. We tried to identify the
genes determining tumor size and to clarify its relationship to the
tumor enlargement in the present experiment. The size distribu-
tion of intestinal tumors in different-week-old mice shows
following two important characteristics (Fig.1). First, the number of
intestinal tumors were conﬁrmed as 55.2 ± 16.3(N ¼ 6),
53.4 ± 4.4(N ¼ 11)and 74.4 ± 3.4(N ¼ 12) in 8, 12 and 30-week-old
ApcMin/þ mice, respectively. If we would expect that the tumors
were developed randomly through lifetime, the mouse carrying 55
tumors at 8-week-old would develop 83 tumors at 12-week-old
and 206 tumors at 30-week-old. Thus, we found that the most part
Fig. 2. Cell proliferation and xenograft model. The graph shows the doubling time of mock- and Tff2-transfected DLD-1 cells (A) and MDCKII cells (B). Mean doubling
time ± standard error of the mean (SEM, n ¼ 3) *P < 0.05, unpaired t-test. Approximate curve line of the volume of xenograft tumors from mock- and Tff2-transfected DLD-1 cells
(C). The data of two stable clones were averaged. Mean tumor volume ± SEM (n ¼ 8 and 9, Tff2 and mock group, respectively) P < 0.0001, second order polynomial regression
analysis.
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number of intestinal tumor was a little ﬂuctuation through a life-
time. Second, the pattern of size distribution shows that the peak
not only shifts to larger size, but also become broader in more-
week-old mice, suggesting additional factors participating to
determine tumor size in addition to time factor. We then, used 30-
week-old mice because variable tumor size was observed in their
small intestine at this age. Because the highest frequency of tumors
size for 30-week-old ApcMin/þ mice were found at 2.5e3 mm in
diameter, we determined to compare gene expression proﬁle be-
tween tumors larger and smaller than 2.5e3 mm. Simultaneously,
we performed histopathological analysis and conﬁrmed that tu-
mors for microarray analysis were adenomataus polyps. Thus, we
supposed that differences of the gene expression levels in excised
tumors primarily depend on size difference rather than malignant
grade.
The large difference of Tff2 expression levels were also observed
when comparing in normal intestinal tissue and small tumors (4.7-
fold higher in small tumors, see Additional ﬁle 3). These results
imply that Tff2 expression is increased at an early stage of tumor-
igenesis in the intestinal mucosa.
The human TFF family, which comprises TFF1, TFF2, and TFF3,
was originally found in a cDNA clone during a search for estrogen-
induced mRNAs in a breast cancer cell line. In the gastrointestinaltract, this family of genes is expressed in themucin layer [9e11] and
is suggested to be involved in the mucosal healing processes
[12e14]. Moreover, TFF2 has been said that it could be a useful
target for therapeutic intervention in gastric cancer because
expression of TFF2 involved gastric cancer invasion [15]. Increased
TFF2 expression in the airway is suggested to promote epithelial
repair in patients with asthma [16]. It is thought that TFF2 promotes
the restoration of the airway epithelia, under the auspices of cell
proliferation and migration [17,18]. Our data are in line with these
results, demonstrating that Tff2 expression accelerated cell prolif-
eration in vitro, particularly in epithelial cells (Fig. 2B). Although, a
possibility that immune modulation by Tff2 would participate on
tumor development as reported [19], Tff2, at last, could enlarge
tumor size independently from immune response, because the
xenograft experiment in our present study used nude mice which
deﬁcient in immune system (Fig. 2C).
In this study, Tff2 expression promoted intestinal adenocarci-
noma cell proliferation in vitro and tumor growth in vivo. These
results raise the possibility that Tff2 plays an important role in in-
testinal tumor enlargement by promoting growth of intestinal tu-
mor cells. For this reason, the intestinal tumor which is highly
expressed of Tff2 at juvenile period was considered to grow faster
and bigger during the same period. Further evidence is required to
support this hypothesis, including clinical samples of human
K. Fujimoto et al. / Biochemical and Biophysical Research Communications 463 (2015) 859e863 863intestinal tumors and further functional analyses concerning TFF2.
In the future, we believe that TFF2may be a novel molecular target
for chemotherapy and chemoprevention by controlling tumor size.
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